Opioid Use Disorder at 34 Weeks: Buprenorphine, Analgesia, and Neonatal Abstinence Syndrome
A 30-year-old G2P1 at 34 weeks 2 days with opioid use disorder is maintained on buprenorphine 16 mg daily. She has been adherent to treatment and has had negative urine drug screens for 6 months. She presents with contractions and is 3 cm dilated. She is concerned about pain control during labor and about the baby withdrawing after birth. She asks whether she should stop buprenorphine before delivery and whether she can receive an epidural. The hospital has a neonatal abstinence syndrome (NAS) protocol and a rooming-in program.
1. Should she stop buprenorphine before delivery? What are the risks of discontinuation?
Read the worked answer
She should not stop buprenorphine abruptly. Discontinuation can precipitate withdrawal, increase the risk of relapse, and jeopardize maternal and fetal stability. Buprenorphine is a partial opioid agonist with a long half-life and is safe in pregnancy; it is associated with less severe NAS than methadone in some studies. The judgment is that continued treatment is safer than discontinuation. If dose adjustment is needed, it should be done in consultation with addiction medicine. The patient should be reassured that continuing treatment is recommended and that the neonatal team will manage NAS.
2. How should labor analgesia be managed, and what are the considerations for neuraxial analgesia?
Read the worked answer
Neuraxial analgesia (epidural or combined spinal-epidural) is appropriate and should not be withheld because of buprenorphine use. Buprenorphine does not contraindicate neuraxial analgesia. However, the anesthesiologist should be aware of the medication and the patient's opioid tolerance. If she has been on buprenorphine, she may require higher doses of local anesthetics or adjuncts. The judgment is that epidural analgesia is safe and should be offered. If she declines, alternative analgesia should be discussed, but opioids should be used cautiously because of tolerance and the risk of withdrawal.
3. What should you counsel about neonatal abstinence syndrome and postpartum care?
Read the worked answer
NAS may occur after delivery, with onset typically 24-72 hours for buprenorphine (sometimes later). The neonate should be monitored with a validated scoring tool (e.g., Finnegan or eat-sleep-console). Rooming-in and breastfeeding are encouraged unless contraindicated; breastfeeding can reduce NAS severity. The mother should continue buprenorphine postpartum and be linked to addiction treatment and social support. The judgment is that continued treatment, rooming-in, and breastfeeding are protective, and that the mother should not be stigmatized. Close collaboration among obstetrics, neonatology, and addiction medicine is essential.